巨噬细胞M2标志物CD163和MRC1在急性髓性白血病中的预后分析  

Prognostic Analysis of Macrophage M2 Markers CD163 and MRC1 in Acute Myeloid Leukemia

作　　者：冯小云 卓英权 秦玉凤 卢茜 袁月 彭美林 李丹[1] 王岚[1] 张鹏 FENG Xiaoyun;ZHUO Yingquan;QIN Yufeng;LU Xi;YUAN Yue;PENG Meilin;LI Dan;WANG Lan;ZHANG Peng(Center of Tissue Engineering and Stem Cell of Guizhou Medical University,Guiyang 550004,Guizhou,China)

机构地区：[1]贵州医科大学组织工程与干细胞中心,贵州贵阳550004

出　　处：《医学信息》2025年第7期1-9,共9页Journal of Medical Information

基　　金：国家自然科学基金地区科学基金项目(编号:81960036);贵州省科技计划项目(编号:黔科合基础-ZK[2021]重点005)。

摘　　要：目的探讨肿瘤相关巨噬细胞M2(M2-TAMs)标志物CD163和MRC1的表达对急性髓系白血病(AML)的生存预后影响。方法通过TCGA和UALCAN对CD163和MRC1进行泛癌分析。使用TARGET、GEPIA2、UALCAN、Kaplan-Meier Plotter和Oncolnc数据库分析CD163和MRC1在AML中差异表达与生存预后。使用TISCH数据库对CD163和MRC1进行单细胞水平分析。结果MRC1在大部分肿瘤组织中表达均下调,且CD163在肿瘤组织表达高于癌旁组织(P<0.05);TCGA、TARGET、GEPIA2、UALCAN、Kaplan-Meier Plotter和Oncolnc数据库中CD163和MRC1高表达的AML患者生存时间较低表达组缩短,为高危因素,差异有统计学意义(P<0.05)。单细胞数据集AML_GSE116256中分析发现,CD163主要在单核巨噬细胞中表达;MRC1主要在单核巨噬细胞、NK细胞和恶性细胞中表达,并通过细胞形态学观察和免疫荧光验证诱导极化M2-TAMs成功。结论与健康对照组相比,AML患者CD163和MRC1呈高表达,且M2-TAMs浸润高的患者预后较差,初步论证CD163和MRC1可能是AML中的一种潜在预后指标。Objective To investigate the effect of the expression of tumor-associated macrophage M2(M2-TAMs)markers CD163 and MRC1 on the survival and prognosis of acute myeloid leukemia(AML).Methods Pan-cancer analysis of CD163 and MRC1 was performed by TCGA and UALCAN.TARGET,GEPIA2,UALCAN,Kaplan-Meier Plotter and Oncolnc databases were used to analyze the differential expression and survival prognosis of CD163 and MRC1 in AML.The TISCH database was used to analyze CD163 and MRC1 at the single cell level.Results The expression of MRC1 was down-regulated in most tumor tissues,and the expression of CD163 in tumor tissues was higher than that in adjacent tissues(P<0.05).By searching TCGA,TARGET,GEPIA2,UALCAN,Kaplan-Meier Plotter and Oncolnc databases,it was found that the survival time of AML patients with high expression of CD163 and MRC1 was shorter than that of low expression group,which was a high risk factor,and the difference was statistically significant(P<0.05).In the single cell data set AML_GSE116256,it was found that CD163 was mainly expressed in mononuclear macrophages,MRC1 was mainly expressed in mononuclear macrophages,NK cells and malignant cells,and the successful induction of polarized M2-TAMs was verified by cell morphological observation and immunofluorescence.Conclusion Compared with healthy controls,patients with AML have high expression of CD163 and MRC1,and patients with high M2-TAMs infiltration have a poor prognosis.CD163 and MRC1 were preliminarily demonstrated as potential prognostic indicators in AML.

关 键 词：急性髓系白血病 肿瘤相关巨噬细胞M2 CD163 MRC1 

分 类 号：R733.71[医药卫生—肿瘤]